MedTrace Logo

Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)

NCT04839146 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-02-17

Study results available
· View outcomes & findings →

Summary

This phase 1 trial aims to assess the safety and tolerability of two doses of ABNCoV2, formulated with and without the adjuvant MF59, in healthy adult volunteers and to identify the dosage and formulation that optimizes the immunogenicity-tolerability ratio 14 days following first vaccination with ABNCoV2.

Conditions

Interventions

BIOLOGICAL

ABNCoV2 Vaccine

SARS-CoV-2 vaccine

Sponsors & Collaborators

  • European Union

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Benjamin Mordmüller, Prof · Stichting Radboud university medical center

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-11
Primary Completion
2021-12-30
Completion
2022-02-25

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04839146 on ClinicalTrials.gov